glp 1 agonist pharmacology Frontiers GLP-1-based therapies for type 2

We realized that no one had comprehensively investigated (the) effectiveness and risks of GLP-1RA across all possible health outcomes

Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

Nagendra et al

Daniel R Quast, Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, Sankt Josef-Hospital, Ruhr-University, D-44791 Bochum, Germany

Journal of Endocrinology

Targeted medicines with few adverse effects may become a reality once these pathways are understood